

WAY

2

embecta is All In for People With Diabetes

To develop and provide solutions that make life better for people living with diabetes.

President & CEO: Devdatt (Dev) Kurdikar

Founded: Spun off from BD in 2022

Employees: 2,000+

Stock Symbol: EMBC

Toll-Free Phone: (844) 823-5433

Address: 300 Kimball Drive, Suite 300
Parsippany, NJ 07054

Website: www.embecta.com



Company Background

embecta is one of the largest pure-play diabetes care companies in the world following its spinoff from Becton, Dickinson and Company (BD) on April 1st, 2022. The company's history in the diabetes care category dates back to 1924 and the development of the world's first specialized insulin syringe. Today, it is the leading producer of diabetes injection devices, manufacturing approximately 8 billion injection devices annually for an estimated 30 million patients.* embecta empowers people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe.

Product Overview

Diabetes can come with unique challenges, and it takes a community to support people living with diabetes as they navigate their care journey. From friends and family members to dietitians, nurses, physicians, and pharmacists — everyone is all in, lending their expertise and encouragement.

embecta is also a part of that community to advance diabetes care by raising awareness of potential complications patients who inject insulin may face, as well as providing educational tools to help improve patient health outcomes.

When it comes to insulin injection technique, nearly 50% of patients reuse their needles, which has been associated with increased risk of developing lipohypertrophy.^{1*} Lipohypertrophy can result in erratic insulin absorption, increased glycemic variability, and unexplained hypoglycemic episodes.² Furthermore, reusing needles may cause them to dull, making injecting more painful.²

Although needle reuse is a prominent issue, there is an opportunity for pharmacists and their team to play a crucial role in helping reduce these risks. As one of the most accessible healthcare

providers, pharmacists have the ability to counsel patients on the importance of using a new needle for every insulin injection and ensuring they have enough supply to do so — but where do you start?

embecta can help facilitate conversations about diabetes management between your pharmacy staff and patients with our Patient Counseling Toolbox. This toolbox contains several educational resources to help lead the conversation about diabetes, including information on:

- HbA1c
- Glycemic Control
- Steps for Proper Injection Technique
- BD Nano™ 2nd Gen Pen Needles and Samples
- And Many More

The items contained in the toolbox can help guide discussions about needle reuse and the benefits of practicing proper injection technique, including using a new needle, rotating injection sites, and shifting to a shorter needle length.³ Ensuring patients have enough needle supply to use a new one with every injection is an important part of their diabetes self-care. As healthcare professionals, pharmacists can help drive this initiative and improve patient outcomes one new needle at a time.

No matter where a patient is on their journey with diabetes, embecta is here to help.

Ordering Information

Order a Patient Counseling Toolbox today at go.embecta.com/pharmacypartner.

*13,289 patients with diabetes who inject insulin participated in an injection technique questionnaire. 38.8% of the 2,711 patients using insulin syringes reported needle reuse. 55.8% of the 11,961 patients using pen needles reported needle reuse.

†A causal relationship has not been established. 13,289 insulin-injecting patients participated in a survey. Needle reuse was assessed through a questionnaire and lipohypertrophy was assessed through a questionnaire and HCP assessment using visual and palpitation method. Logistic regression analysis was used to find the association between pen needle reuse and LH (P= .02).

1. Frid AH, Hirsch IJ, Menchior AR, Morel DR, Strauss KW. Worldwide injection technique questionnaire study: population parameters and injection practices. *Mayo Clin Proc.* 2016;91(9):1212-1223.

2. American Diabetes Association. Standards of Medical Care in Diabetes - 2023. *Diabetes Care.* 2023;46(Suppl 1):S1-298.

3. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. *Mayo Clin Proc.* 2016;91(9):1231-1255.